Topical calcineurin inhibitors (TCIs) are widely used as an alternative to topical corticosteroids (TCSs) in treating of atopic dermatitis, but their risk versus benefit compared with TCSs remains unclear.
Objective
We performed a systematic review of the efficacy, safety, and cost-effectiveness of TCI compared with TCS and emollients.
Methods
Published meta-analysis, systematic reviews, and individual studies from January 2005 to January 2015 on the comparative efficacy, safety, and cost-effectiveness of TCI against emollients and TCS were included.
Results
Tacrolimus is comparable to TCS in efficacy, safety profile, and cost-effectiveness. Pimecrolimus has a similar safety profile compared with TCS, emollients, and tacrolimus. It is superior to emollients but inferior to TCS and tacrolimus in efficacy and cost-effectiveness. The association of tacrolimus with malignancy remains uncertain.
Conclusions
Tacrolimus is an efficacious and cost-effective alternative to TCS, but its benefits need to be weighed against its still uncertain risk for malignancy. Pimecrolimus is appropriate for mild atopic dermatitis when TCS or tacrolimus is unsuitable.
Get full access to this article
View all access options for this article.
References
1.
Van Der MeerJB, GlazenburgEJ, MulderPG, et al.The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol, 1999; 140 (6): 1114–1121.
2.
HanifinJ, GuptaAK, RajagopalanR. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol, 2002; 147 (3): 528–537.
3.
Berth-JonesJ, DamstraRJ, GolschS, et al.Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ, 2003; 326 (7403): 1367.
4.
HultschT, KappA, SpergelJ. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology, 2005; 211 (2): 174–187.
5.
StuetzA, BaumannK, GrassbergerM, et al.Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus. Int Arch Allergy Immunol, 2006; 141 (3): 199–212.
6.
WongR, LinAN. Efficacy of topical calcineurin inhibitors in vitiligo. Int J Dermatol, 2013; 52 (4): 491–496.
7.
WangC, LinA. Efficacy of topical calcineurin inhibitors in psoriasis. J Cutan Med Surg, 2014; 18 (1): 8–14.
8.
HornEJ, DommS, KatzHI, et al.Topical corticosteroids in psoriasis: strategies for improving safety. J Eur Acad Dermatol Venereol, 2010; 24 (2): 119–124.
ReitamoS, Van LeentEJ, HoV, et al.Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol, 2002; 109 (3): 539–546.
11.
NakagawaH.Comparison of the efficacy and safety of 0.1% tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis: review of randomised, double-blind clinical studies conducted in Japan. Clin Drug Investig, 2006; 26 (5): 235–246.
12.
DossN, ReitamoS, DubertretL, et al.Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial. Br J Dermatol, 2009; 161 (2): 427–434.
13.
HebertAA, KooJ, FowlerJ, et al.Desoximetasone 0.25% and tacrolimus 0.1% ointments versus tacrolimus alone in the treatment of atopic dermatitis. Cutis, 2006; 78 (5): 357–363.
14.
MandelinJ, RemitzA, VirtanenH, et al.One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: a randomized, double-blind, comparative trial. Acta Derm Venereol, 2010; 90 (2): 170–174.
15.
ReitamoS, RustinM, RuzickaT, et al.Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol, 2002; 109 (3): 547–555.
16.
ReitamoS, HarperJ, BosJD, et al.0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol, 2004; 150 (3): 554–562.
17.
ReitamoS, OrtonneJP, SandC, et al.A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol, 2005; 152 (6): 1282–1289.
18.
HofmanT, CranswickN, KunaP, et al.Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children. Arch Dis Child, 2006; 91 (11): 905–910.
19.
BieberT, VickK, Folster-HolstR, et al.Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy, 2007; 62 (2): 184–189.
20.
DossN, KamounMR, DubertretL, et al.Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment. Pediatr Allergy Immunol, 2010; 21 (2 Pt 1): 321–329.
21.
GradmanJ, WolthersOD. Short-term growth in children with eczema during treatment with topical mometasone furoate and tacrolimus. Acta Paediatr, 2007; 96 (8): 1233–1237.
22.
TorokHM, Maas-IrslingerR, SlaytonRM. Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis. Cutis, 2003; 72 (2): 161–166.
23.
HungSH, LinYT, ChuCY, et al.Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Ann Allergy Asthma Immunol, 2007; 98 (1): 51–56.
24.
SikderA, Al MamunS, KhanRM, et al.Topical 0.03% tacrolimus ointment, 0.05% clobetasone butyrate cream alone and their combination in older children with atopic dermatitis—an open randomized comparative study. J Pak Assoc Dermatol, 2005; 15: 304–312.
25.
BrenemanD, FleischerABJr, AbramovitsW, et al.Tacrolimus ointment with and without topical steroids in patients with moderate to severe atopic dermatitis. J Am Acad Dermatol, 2006; 54 (3,Suppl 1): AB88 Abstr. P832.
26.
SvenssonA, ChambersC, GånemoA, et al.A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Curr Med Res Opin, 2011; 27 (7): 1395–1406.
27.
AshcroftDM, ChenLC, GarsideR, et al.Topical pimecrolimus for eczema. Cochrane Database Syst Rev, 2007; 4: CD005500.
EichenfieldLF, LuckyAW, BoguniewiczM, et al.Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol, 2002; 46 (4): 495–504.
30.
HoVC, GuptaA, KaufmannR, et al.Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr, 2003; 142 (2): 155–162.
31.
LugerT, Van LeentEJ, GraeberM, et al.SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol, 2001; 144 (4): 788–794.
32.
BarbaJ, BeiranaA, CohenV, et al.Pimecrolimus cream 1% is effective, well tolerated and safe in infants and children with atopic eczema of the face. J Eur Acad Dermatol Venereol, 2003; 17 (Suppl 3:P2.35).
33.
Novartis (protocol CASM981C2442). A 12-week multicenter study consisting of a 6-week double-blind, randomized, vehicle controlled, parallel group phase, followed by a 6 week open label phase, to assess the safety and efficacy of pimecrolimus cream 1% in mild to moderate head and neck atopic dermatitis of patients intolerant of topical corticosteroid. 2006. Available at: www.novartisclinicaltrials.com/clinicaltrialrepository/public/login.jsp?target=%2Fclinicaltrialrepository%2Fpublic%2Fmain.jsp. Accessed October31, 2006.
KaufmannR, BieberT, HelgesenAL, et al.Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. Allergy, 2006; 61 (3): 375–381.
36.
LeoHL, BenderBG, LeungSB, et al.Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis. J Allergy Clin Immunol, 2004; 114 (3): 691–693.
37.
StaabD, KaufmannR, BräutigamM, et al.Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents’ quality of life: a multicenter, randomized trial. Pediatr Allergy Immunol, 2005; 16 (6): 527–533.
38.
WhalleyD, HuelsJ, McKennaSP, et al.The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents’ quality of life in the treatment of pediatric atopic dermatitis. Pediatrics, 2002; 110 (6): 1133–1136.
39.
KappA, PappK, BinghamA, et al.Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol, 2002; 110 (2): 277–284.
40.
ThaciD, Folster-HolstR, HogerP, et al.Pimecrolimus cream 1% is effective in the treatment of atopic eczema in infants irrespective of clinical score. J Eur Acad Dermatol Venereol, 2003; 17 (Suppl 3:P2.37).
Novartis (protocol ASM981C2315). A 26-week, randomized, multicenter, parallel-group, double-blind, vehicle-controlled study to evaluate the incidence of atopic dermatitis flares when pimecrolimus cream 1% is used at the first signs and/or symptoms of atopic dermatitis and its safety and tolerability in children and adolescents 2–17 years of age. 2005. Available at: www.novartisclinicaltrials.com/clinicaltrialrepository/public/login.jsp?target=%2Fclinicaltrialrepository%2Fpublic%2Fmain.jsp. Accessed August1, 2006.
44.
Novartis (protocol ASM981C2316). A 26-week, randomized, multicenter, parallel-group, double-blind, vehicle-controlled study to evaluate the incidence of atopic dermatitis flares when pimecrolimus cream 1% is used at the first signs and/or symptoms of atopic dermatitis and its safety and tolerability in adults 18 years of age and older. 2005. Available at: www.novartisclinicaltrials.com/clinicaltrialrepository/public/login.jsp?target=%2Fclinicaltrialrepository%2Fpublic%2Fmain.jsp. Accessed August1, 2006.
45.
Novartis (protocol CASM981C1301) Norvatis CASM981C1301. Confirmatory study in pediatric patients with atopic dermatitis—multicenter, randomized, double-blind, parallel-group, vehicle-controlled study with a 26-weeks treatment phase to determine the efficacy, safety of pimecrolimus cream for long-term treatment of pediatric patients with atopic dermatitis. 2005. Available at: www.novartisclinicaltrials.com/clinicaltrialrepository/public/login.jsp?target=%2Fclinicaltrialrepository%2Fpublic%2Fmain.jsp. Accessed August1, 2006.
MeurerM, Folster-HolstR, WozelG, et al.Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology, 2002; 205 (3): 271–277.
48.
SiegfriedE, KormanN, MolinaC, et al.Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis. J Dermatolog Treat, 2006; 17 (3): 143–150.
49.
WahnU, BosJD, GoodfieldM, et al.Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics, 2002; 110 (1 Pt 1): e2.
LugerTA, LahfaM, Folster-HolstR, et al.Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat, 2004; 15 (3): 169–178.
53.
KempersS, BoguniewiczM, CarterE, et al.A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol, 2004; 51 (4): 515–525.
54.
PallerAS, LebwohlM, FleischerABJr, et al.Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol, 2005; 52 (5): 810–822.
TennisP, GelfandJM, RothmanKJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol, 2011; 165 (3): 465–473.
57.
HuiRL, LideW, ChanJ, et al.Association between exposure to topical tacrolimus or pimecrolimus and cancers. Ann Pharmacother, 2009; 43 (12): 1956–1963.
58.
SchneeweissS, DohertyM, ZhuS, et al.Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. Dermatology, 2009; 219 (1): 7–21.
59.
ArellanoFM, WentworthCE, AranaA, et al.Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol, 2007; 127 (4): 808–816.
60.
ArellanoFM, AranaA, WentworthCE, et al.Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol, 2009; 123 (5): 1111–1116, 1116.e1–1116.e13.
61.
MargolisDJ, HoffstadO, BilkerW. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology, 2007; 214 (4): 289–295.
62.
YokotaK, GillTJ 3rd, ShinozukaH. Effects of oral versus topical administration of cyclosporine on phorbol ester promotion of murine epidermal carcinogenesis. Cancer Res, 1989; 49 (16): 4586–4590.
63.
GschwendtM, KittsteinW, MarksF. Cyclosporin A inhibits phorbol ester-induced cellular proliferation and tumor promotion as well as phosphorylation of a 100-kd protein in mouse epidermis. Carcinogenesis, 1987; 8 (2): 203–207.
64.
TranC, LübbeJ, SorgO, et al.Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology, 2005; 211 (4): 341–347.
65.
GarsideR, SteinK, CastelnuovoE, et al.The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation. Health Technol Assess, 2005; 9 (29): iii, xi-xiii,1–230.
66.
PittM, GarsideR, SteinK. A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema. Br J Dermatol, 2006; 154 (6): 1137–1146.
67.
HjelmgrenJ, SvenssonA, JörgensenET, et al.Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data. Br J Dermatol, 2007; 156 (5): 913–921.
68.
AbramovitsW, BoguniewiczM, PrendergastMM, et al.Comparisons of efficacy and cost-effectiveness of topical immunomodulators in the management of atopic dermatitis. J Med Econ, 2003; 6: 1–14.
69.
TanejaC, AntayaRJ, BergerA, et al.Cost-effectiveness of tacrolimus ointment versus pimecrolimus cream in adults with atopic dermatitis. J Drugs Dermatol, 2010; 9 (4): 372–376.
70.
HealyE, BentleyA, FidlerC, et al.Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. Br J Dermatol, 2011; 164 (2): 387–395.
71.
ThaciD, ChambersC, SidhuM, et al.Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months. J Eur Acad Dermatol Venereol, 2010; 24 (9): 1040–1046.
72.
WollenbergA, SidhuMK, OdeyemiI, et al.Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol, 2008; 159 (6): 1322–1330.
73.
EllisCN, DrakeLA, PrendergastMM, et al.Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. J Am Acad Dermatol, 2003; 48 (4): 553–563.
74.
MeurerM, LubbeJ, KappA, et al.The role of pimecrolimus cream 1% (Elidel) in managing adult atopic eczema. Dermatology, 2007; 215 (Suppl 1): 18–26.
75.
EllisCN, KahlerKH, GruegerJ, et al.Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2–17 years of age. Am J Clin Dermatol, 2006; 7 (2): 133–139.
76.
FollandS, GoodmanAC, StanoM.Chapter 4: economic efficiency and cost-benefit analysis. In: The Economics of Health and Health Care. 6th ed. Boston, MA: Prentice Hall; 2010.
